史赛克以8.35亿美元收购由Biostar Capital支持的Amplitude Vascular Systems，这一交易凸显了密歇根州医疗技术生态系统的雄厚实力与吸引力。此次收购不仅标志着该区域在创新医疗设备领域的重要地位，也反映了投资者对本地孕育的高增长企业的持续信心。交易的成功完成，预计将进一步加强史赛克在血管介入治疗领域的产品组合，同时为密歇根州的医疗科技产业注入新的发展动力。
史赛克以8.35亿美元收购由Biostar Capital支持的Amplitude Vascular Systems，这一交易凸显了密歇根州医疗技术生态系统的雄厚实力与吸引力。此次收购不仅标志着该区域在创新医疗设备领域的重要地位，也反映了投资者对本地孕育的高增长企业的持续信心。交易的成功完成，预计将进一步加强史赛克在血管介入治疗领域的产品组合，同时为密歇根州的医疗科技产业注入新的发展动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.